AbbVie ABBV Ubrelvy — Net revenues

Other product segments

Similar metrics at other companies

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

ESP

ESPRProduct sales, net — Total Revenues

$43.4M+24.3%

XER

XERSProduct revenue, net — Product revenue, net

$82.45M+42.6%

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

ACOGProduct Net — Revenue

$3.5M+910%

GERNProduct revenue, net — Total revenues

$51.77M+31.3%

Questions, answered.

What is AbbVie's ubrelvy — net revenues?

AbbVie (ABBV) reported ubrelvy — net revenues of $339M in Q1 2026.

How has AbbVie's ubrelvy — net revenues changed year-over-year?

AbbVie's ubrelvy — net revenues increased by 41.3% year-over-year, from $240M to $339M.

What is the long-term trend for AbbVie's ubrelvy — net revenues?

Over 4 years (2021 to 2025), AbbVie's ubrelvy — net revenues has grown at a 23.2% compound annual growth rate (CAGR), from $552M to $1.27B.

What does ubrelvy — net revenues mean?

This metric represents the total gross sales of a specific pharmaceutical product line after accounting for returns, allowances, and rebates. It reflects the commercial performance and market adoption of the therapeutic asset within the company's broader portfolio. Monitoring this figure helps investors assess the revenue contribution and growth trajectory of key branded drugs.